• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

How PSMA-PET scans are changing clinical practice


Accurate imaging is a critical component of prostate cancer management for a number of reasons, including tumor localization, disease staging, and detecting recurrence. PSMA-PET scan — named a top medical innovation by Cleveland Clinic in 2022 — offers a new imaging approach for this patient population that has the ability to detect recurrence earlier and, in turn, enable clinicians to implement treatment sooner.

“PSMA imaging is an exciting innovation that holds significant promise for the treatment of prostate cancer,” notes Rahul Tendulkar, MD, a radiation oncologist at Cleveland Clinic. “To better tailor treatments for our patients, we must be able to stratify risk and accurately determine disease stage. Therefore, imaging capabilities are a key component of managing these patients successfully.”

What is PSMA-PET scan?

The conventional imaging methods typically used for prostate cancer patents, including CT, MRI, and bone scan, have limitations when it comes to disease detection, according to Steve Huang, MD, Nuclear Medicine Department, Cleveland Clinic.

Compared with other imaging options, PSMA-PET scan has greater sensitivity and can detect metastases sooner, allowing clinicians to better serve patients and make treatment decisions earlier, he says. “PSMA-PET scan makes it possible to see a smaller volume of cells, which allows oncologists to localize the disease and determine the best approach to treatment.”

“PSMA, or prostate-specific membrane antigen, is a protein on the surface of many prostate cells and it has been shown that radiotracers tagged to PSMA can identify early, low-volume sites of lymph node or distant metastases of prostate cancer,” explains Dr. Tendulkar.

The first PSMA-targeted PET imaging drug for prostate cancer—Gallium 68 PSMA-11 (Ga 68 PSMA-11) — was approved by the FDA in 2020 for patients with suspected prostate cancer recurrence and metastasis. This approval was based on phase III clinical trials that demonstrated a significant increase in accuracy for the detection of prostate cancer compared with standard imaging modalities. In 2021, a second FDA approval followed for Pylarify (piflufolastat F 18) for the same indication.

Several institutions have adopted this technology since, including Cleveland Clinic, which integrated PSMA-PET scans into practice in September 2021. However, this is not a new area of interest for experts at the facility. Warren Heston, PhD, a basic scientist at Cleveland Clinic Lerner Research Institute, first discovered and cloned the PSMA protein in the early 1990s. Researchers have also participated in clinical trials evaluating the PSMA imaging agent rhPSMA-7.3 (18F).

Practice changing approach

While use of this approach has only recently started in clinical practice, Dr. Tendulkar has already observed a shift in the management of prostate cancer patients at Cleveland Clinic.

“Our ability to obtain PSA-PET scans has really been a game changer, and I don’t use that term loosely,” he says. “Historically, if a patient had a rising PSA, we would get a CT scan and a bone scan. And, oftentimes, either we wouldn’t see anything obvious or, if we did, it was widespread throughout the body at which point there’s really no curative option.

“Since integrating this new approach, we have found that PSMA-PET scan can find a few sites of recurrent prostate cancer,” he continues. “And so, if we can identify recurrence before it’s widespread, we may be able to intervene earlier and perhaps alter the natural history of their disease in a way that is associated with a low risk of toxicity.”

For example, a patient, who has undergone prior radiation therapy to the prostate, develops a rising PSA and a local recurrence is discovered. “A PSMA-PET scan that demonstrates no evidence of spread into the lymph nodes or distant metastatic sites gives us more reassurance to treat the recurrent area within the prostate in a potentially curative fashion for a second chance of success,” says Dr. Tendulkar. “If we can be more selective in who may be treated with a salvage retreatment, we may improve our selection criteria to choose patients more likely to benefit.”

To date, PSMA-PET scan has been used in a few hundred patients at Cleveland Clinic and there are ongoing efforts for continued growth and expansion. “There is significant demand for this technology among our patients,” says Dr. Huang, who notes that they are currently scheduling about one month out. “Given the potential impact of this approach, increasing access to PSMA-PET scans is a top priority. We are working hard to open more scanning sites and expand the availability throughout our system.”

Related Videos
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
David I. Lee, MD, FACS, answers a question during a video interview
A panel of 4 experts on prostate cancer
A panel of 4 experts on prostate cancer
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.